Year: 2024
Type: article
Abstract: Lecanemab is a groundbreaking treatment for Alzheimer’s disease, showing significant promise in slowing cognitive decline in patients with early-stage disease. Lecanemab is the most recent monoclonal antibody to target beta-amyloid and is licensed only for the treatment of mild cognitive impairment or mild dementia associated with Alzheimer's disease. Lecanemab represents a fresh approach to targeting the pathophysiology underlying the condition, and the encouraging outcomes of the Phase 3 trial provide hope to patients and their families. Although more research is need to determine lecanemab's safety and efficacy, the results of the Phase 3 trial suggest that it could greatly improve AD treatment options. This review explores the mechanism of action, clinical trial data, potential impacts, and future directions for this monoclonal antibody therapy.
Authors: Vankodoth Sireesha, N. Chaitanya, Meghana. Ch, K. Megana
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4404546431